Genetically Predicted Phosphate and Cardiovascular Disease: A Mendelian Randomization Study

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2022 Oct 24

PMID 36277795

Authors

Jiniu Huang

Chenyun Zhang

Qinyan Gong

Ying Gao

Xiaojie Xie

Jun Jiang

Affiliations

Soon will be listed here.

Abstract

Background: Extensive epidemiological studies have highlighted the correlation between serum phosphate and cardiovascular diseases. The present study aims to determine whether genetically predicted serum phosphate is causally associated with the distinct subtypes of cardiovascular events through the use of Mendelian randomization (MR) analysis.

Methods: Independent and strongly correlated single-nucleotide polymorphisms (SNPs) for serum phosphate were extracted from publicly available genome-wide association studies. Summary statistics of cardiovascular diseases were derived from large-scale consortiums, including HERMES and FinnGen biobank. MR-Egger, weighted median, inverse variance weighted, pleiotropy residual sum and outlier (MR-PRESSO) methods and MR using robust adjusted profile score (MR-RAPS) were employed to analyze causality. The sensitivity analyses comprised heterogeneity, horizontal pleiotropy, and leave-one-out approaches; these were used to ensure the stability of the results.

Results: Our study demonstrated that increased genetically predicted serum phosphate is causally associated with a higher risk of valvular heart disease (VHD) [For VHD including rheumatic fever: odds ratio (OR) = 2.45; 95% confidence interval (CI), 1.52-3.94; = 0.0002; for non-rheumatic VHD: OR = 6.58; 95% CI, 2.50-17.32; = 0.0001]. However, no causal association was detected between serum phosphate and other common cardiovascular diseases (including coronary heart disease, heart failure, atrial fibrillation, and essential hypertension).

Conclusions: The results indicate strong causality between serum phosphate and valvular heart disease. Serum phosphate-lowering therapy within the physiological range may represent a novel therapeutic method for valvular heart disease.

References

Ye Z, Zheng J . Verification of the Role of ADAMTS13 in the Cardiovascular Disease Using Two-Sample Mendelian Randomization. Front Genet. 2021; 12:660989. PMC: 8280495. DOI: 10.3389/fgene.2021.660989. View

Coffey S, Roberts-Thomson R, Brown A, Carapetis J, Chen M, Enriquez-Sarano M . Global epidemiology of valvular heart disease. Nat Rev Cardiol. 2021; 18(12):853-864. DOI: 10.1038/s41569-021-00570-z. View

Navarro-Gonzalez J, Mora-Fernandez C, Muros M, Herrera H, Garcia J . Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study. Clin J Am Soc Nephrol. 2009; 4(10):1646-54. PMC: 2758261. DOI: 10.2215/CJN.02420409. View

Kamat M, Blackshaw J, Young R, Surendran P, Burgess S, Danesh J . PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics. 2019; 35(22):4851-4853. PMC: 6853652. DOI: 10.1093/bioinformatics/btz469. View

Jiang Q, Chen M . Assessing causality in associations of lipid levels with aortic valve stenosis. Eur Heart J. 2020; 41(28):2713. DOI: 10.1093/eurheartj/ehaa371. View

Bhadada S, Rao S . Role of Phosphate in Biomineralization. Calcif Tissue Int. 2020; 108(1):32-40. DOI: 10.1007/s00223-020-00729-9. View

Michigami T, Kawai M, Yamazaki M, Ozono K . Phosphate as a Signaling Molecule and Its Sensing Mechanism. Physiol Rev. 2018; 98(4):2317-2348. DOI: 10.1152/physrev.00022.2017. View

Larsson S, Gill D, Mason A, Jiang T, Back M, Butterworth A . Lipoprotein(a) in Alzheimer, Atherosclerotic, Cerebrovascular, Thrombotic, and Valvular Disease: Mendelian Randomization Investigation. Circulation. 2020; 141(22):1826-1828. PMC: 7614586. DOI: 10.1161/CIRCULATIONAHA.120.045826. View

Villa-Bellosta R . Vascular Calcification: Key Roles of Phosphate and Pyrophosphate. Int J Mol Sci. 2021; 22(24). PMC: 8708352. DOI: 10.3390/ijms222413536. View

10.

Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan N, Thompson J . A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med. 2017; 36(11):1783-1802. PMC: 5434863. DOI: 10.1002/sim.7221. View

11.

Corbin L, Richmond R, Wade K, Burgess S, Bowden J, Davey Smith G . BMI as a Modifiable Risk Factor for Type 2 Diabetes: Refining and Understanding Causal Estimates Using Mendelian Randomization. Diabetes. 2016; 65(10):3002-7. PMC: 5279886. DOI: 10.2337/db16-0418. View

12.

Ai S, Zhang J, Zhao G, Wang N, Li G, So H . Causal associations of short and long sleep durations with 12 cardiovascular diseases: linear and nonlinear Mendelian randomization analyses in UK Biobank. Eur Heart J. 2021; 42(34):3349-3357. DOI: 10.1093/eurheartj/ehab170. View

13.

Xu H, Liu Q, Cao K, Ye Y, Zhang B, Li Z . Distribution, Characteristics, and Management of Older Patients With Valvular Heart Disease in China: China-DVD Study. JACC Asia. 2022; 2(3):354-365. PMC: 9627799. DOI: 10.1016/j.jacasi.2021.11.013. View

14.

Burgess S, Thompson S . Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011; 40(3):755-64. DOI: 10.1093/ije/dyr036. View

15.

Bowden J, Davey Smith G, Burgess S . Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015; 44(2):512-25. PMC: 4469799. DOI: 10.1093/ije/dyv080. View

16.

Verbanck M, Chen C, Neale B, Do R . Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018; 50(5):693-698. PMC: 6083837. DOI: 10.1038/s41588-018-0099-7. View

17.

Peng H, Wang S, Wang M, Ye Y, Xue E, Chen X . Nonalcoholic fatty liver disease and cardiovascular diseases: A Mendelian randomization study. Metabolism. 2022; 133:155220. DOI: 10.1016/j.metabol.2022.155220. View

18.

Park K, Lee Y, Park G, Park J, Kim Y, Yang D . Association between serum phosphorus and subclinical coronary atherosclerosis in asymptomatic Korean individuals without kidney dysfunction. Am J Clin Nutr. 2020; 112(1):66-73. DOI: 10.1093/ajcn/nqaa091. View

19.

Dhingra R, Gona P, Benjamin E, Wang T, Aragam J, DAgostino Sr R . Relations of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in the community. Eur J Heart Fail. 2010; 12(8):812-8. PMC: 2913049. DOI: 10.1093/eurjhf/hfq106. View

20.

Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G . Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005; 112(17):2627-33. DOI: 10.1161/CIRCULATIONAHA.105.553198. View